Until law, GLP-1 drugs were used to treat diabetes, obesity and even the recent evidences suggest that it could as well be used to treat chronic kidney problems. There is yet another research, published in JAMA Psychiatry on February 25, titled Once-Weekly Semaglutide in Adults With Alcohol Use Disorder: A Randomized Clinical Trial that explores if GLP-1 receptor agonist semaglutide reduce alcohol consumption and cravings in adults with alcohol use disorder.

What Do Studies Say?

The research was conducted over a period of 9 weeks, where in the randomized clinical trial, the participants who were administered semaglutide, it led to reductions in some but not all measures of weekly consumptions. It also reduced weekly alcohol and craving related to placebo, and also led to a greater relative reduction in cigarettes per day.

The research also found that weekly injections of semaglutide, which is the active ingredient in weight loss drugs like Wegovy also helped reduce cravings in people with alcohol use disorder.

The lead author Christian Hendershot said that these findings will help in developing new approaches to treat alcoholism. "Two drugs currently approved to reduce alcohol consumption aren't widely used. The popularity of Ozempic and other GLP-1 receptor agonists increases the chances of broad adoption of these treatments for alcohol use disorder," said Hendershot in news release by the University of Southern California's Institute for Addiction Research, where he is the director.

The study is government-funded research and was funded by the National Institute on Alcohol Abuse and Alcoholism, part of the National Institutes of Health.

How Was The Study Conducted?

The study was small, and took in account for only 48 adults over two months, thus experts say that it is not yet clear how safe these drugs are for people who do not need to lose weight. Though the results do add up with the evidence form animal studies on drugs like Ozempic and Wegovy on how it helps manage cravings, not just for food, but also for tobacco and alcohol. Scientists are also studying these drugs on smokers, people with opioid addiction and cocaine users.

Co-author Dr Klara Klein of the University of North Carolina at Chapel Hill who treats people with obesity and diabetes said, "This is such promising data. And we need more of it. We frequently will hear that once people start these medications that their desire to drink is very reduced, if not completely abolished."

Why Does It Work So Well Against Alcoholism?

The GLP-1 receptor agonists work by mimicking hormones GLP-1 in the gut and brain that regulates appetite and feelings of fullness. This response is what helps one lose weight, and what helps one curb their craving for alcohol. These drugs that mimic the functioning of your brain, which is responsible to tell your body when to stop consuming, are the same hormones that tell your body about other kinds of consumptions, including alcohol. Therefore by consuming the weight loss drugs one can treat alcohol use disorder.

However, the researchers have pointed out on the limited data on the research and have suggested to continue using the three approved drugs by the National Institute on Alcohol Abuse and Alcoholism and Substance Abuse and Mental Health Services Administration, namely, Disulfiram, Naltrexone, and Acamprosate to treat alcohol use disorder until large studies confirm these findings.

The Ebola outbreak in the Democratic Republic of Congo continues to worsen, with cases rising to 1,155 and deaths climbing to 304, as per the latest government data.

The figures represent the total confirmed cases as of June 24, according to a situation report which documented 37 new cases and five new deaths in the previous 24 hours. Ituri, North Kivu and South Kivu remain the most affected provinces in Congo.

Experimental treatments

Also read: Ebola Outbreak: The Unique Symptoms Seen In Patients Infected With Bundibugyo

The US is now providing doses of an experimental Ebola treatment developed by Mapp Biopharmaceutical for clinical trials in Congo.

The experimental therapy, known as MBP134, was developed by San Diego-based Mapp Biopharmaceutical. While the US had previously kept its stockpile for potential use in exposed American citizens, it is now making doses available to support clinical research in Congo. This is the first time Washington has publicly committed stockpiled supplies of the treatment for a broader international trial.

According to the World Health Organization, researchers will test MBP134 both on its own and alongside the antiviral drug remdesivir, marketed as Veklury. Remdesivir became widely known during the COVID-19 pandemic and is being evaluated to see whether it can improve outcomes when combined with the antibody treatment.

Ebola: Scientists Lack Access To Virus Samples

The ongoing outbreak is being driven by the rare Bundibugyo strain, for which no approved vaccine or treatment exists. However, scientists racing to develop vaccines and therapies are hampered by the lack of a viable sample of the virus.

“There’s nothing like having the authentic isolate,” said Thomas Geisbert, Professor of microbiology and immunology at the University of Texas Medical Branch in Galveston, who helped develop previous Ebola vaccines, Bloomberg reported.

“Despite so many cases, the global scientific community has not obtained a clinical sample to isolate the virus for the needed animal challenge studies,” added Jennifer Serwanga, head of immunology at the Uganda Virus Research Institute, the report said.

Ebola: WHO Warns Spread to South Sudan

Further, as per a new WHO modelling study published in The Lancet, the growing Congo Ebola outbreak, which has already spread to Uganda, has a 70 per cent chance of reaching South Sudan soon.

The study combined epidemic modelling with spillover estimation to quantify regional risks associated with the 2026 Ituri outbreak using laboratory-confirmed case data from WHO Situation Reports (33 cases as of May 18, 2026, to 598 cases as of June 8, 2026), with projections extending 12 weeks from May 18 to Aug. 10, 2026. It also integrates operational preparedness considerations relevant for neighboring countries.

The report showed that even with the intensified response within DR Congo, uncertainty remains around reported case numbers due to the low rate of contact tracing.

“Sustained control nonetheless remains the primary determinant of regional risk: importation into Uganda is already established, and South Sudan must continue to reinforce infection prevention and control, rapid response capacity, and cross-border surveillance under International Health Regulations 2005,” said researchers from the WHO Regional Office for Africa, Nairobi, Kenya.

The report called for:

1. Enhanced surveillance at formal and informal points of entry to detect suspected cases early and prevent silent transmission.
2. Strengthen infection prevention and control (IPC) measures in front-line health facilities to reduce nosocomial transmission and protect health-care workers.
3. Train, equip, and pre-position rapid response teams for immediate deployment.

The United States is now providing doses of an experimental Ebola treatment developed by Mapp Biopharmaceutical for clinical trials in the Democratic Republic of Congo, where a growing outbreak of the Bundibugyo strain has infected more than 1,000 people and claimed over 250 lives. The decision marks a significant shift from the U.S. government's earlier stance, which limited access to the drug to Americans considered at high risk of exposure.

Health officials are racing to find effective ways to contain the outbreak, as there are currently no approved vaccines or treatments specifically designed for the Bundibugyo strain of Ebola. A small number of cases and deaths have also been reported in neighboring Uganda, raising concerns about the disease spreading further across the region.

The experimental therapy, known as MBP134, was developed by San Diego-based Mapp Biopharmaceutical. While the U.S. had previously kept its stockpile for potential use in exposed American citizens, it is now making doses available to support clinical research in Congo. This is the first time Washington has publicly committed stockpiled supplies of the treatment for a broader international trial.

According to the World Health Organization, researchers will test MBP134 both on its own and alongside the antiviral drug remdesivir, marketed as Veklury. Remdesivir became widely known during the COVID-19 pandemic and is being evaluated to see whether it can improve outcomes when combined with the antibody treatment.

Also Read: Nutritional Foods That Help Keep Cholesterol Under Control

Ebola Situation In Western Africa

The confirmed cases in the Ebola outbreak in the Democratic Republic of Congo (DRC) have reached the highest total ever recorded during the first month of an outbreak in Africa, according to the World Health Organization (WHO).

As of June 22, confirmed Ebola cases in Congo had risen to 1,094 and deaths to 277, according to the DRC Ministry of Health. The WHO raised concerns about the rapid spread of the deadly virus and the challenges facing containment efforts.

“This is the largest number of confirmed cases in the first month of an Ebola disease outbreak in Africa,” said Dr Abdirahman Mahamud, Director, Health Emergency Alert and Response Operations at WHO, during a press briefing in Geneva.

"What is important is we need to scale up and this outbreak is moving faster than us," he told reporters after returning from Bunia last week.

Mahamud also noted signs of hope, highlighting a quick increase in the number of Ebola beds to over 500 in the past fortnight and signs that community resistance and violent resistance to Ebola responders was beginning to abate.

As of June 24, Uganda had recorded 20 confirmed Ebola cases, including two fatalities. The latest infection was identified on June 21, with no additional cases reported afterward. Of the confirmed infections, 15 were linked to travel from the Democratic Republic of the Congo (DRC), while five resulted from local transmission. Among the nine cases with available location data, eight were detected in Kampala and one in the neighboring Wakiso District.

Chemotherapy is often considered the most challenging aspect of cancer treatment due to its wide range of side effects. However, new advances in targeted therapies may soon reduce the need for conventional chemotherapy for some breast cancer patients.

Two drugs developed by pharmaceutical giants AstraZeneca and Gilead Sciences have shown encouraging results in treating triple-negative breast cancer (TNBC), one of the most aggressive and difficult-to-treat forms of the disease.

Triple-negative breast cancer lacks three key receptors commonly targeted by standard breast cancer therapies, making many conventional treatments ineffective.

In recent weeks, the US Food and Drug Administration (FDA) approved two targeted therapies—Datroway, developed by AstraZeneca in partnership with Daiichi Sankyo, and Trodelvy from Gilead Sciences—as first-line treatment options for certain patients with advanced triple-negative breast cancer.

Why These Drugs Are Better Than Chemo?

Both Datroway and Trodelvy belong to a class of medicines known as antibody-drug conjugates (ADCs). These therapies use antibodies to identify proteins present on most triple-negative breast cancer cells and deliver a potent dose of chemotherapy directly to the tumor.

The approach is designed to minimize damage to healthy tissues compared with traditional chemotherapy, which affects rapidly dividing cells throughout the body. Clinical trials showed that both drugs reduced the risk of disease progression by about 40% compared with standard chemotherapy, Washington Post reported.

“For seven out of 10 patients with metastatic triple-negative breast cancer who are not candidates for immunotherapy, chemotherapy has remained the only treatment option," said Arlene Brothers, Executive Director, Triple Negative Breast Cancer Foundation, in a statement.

The new drugs for the first time, will pave the way "for these patients will have a new standard of care beyond traditional chemotherapy at the outset of their treatment.”

Efficacy of Trodelvy And Datroway

Gilead's approval is based on two clinical trials that evaluated how effectively Trodelvy delayed tumor growth. When used alone, Trodelvy reduced the risk of tumor progression or death by 38% compared with chemotherapy in patients who were not eligible for immunotherapy.

Among patients eligible for immunotherapy—approximately 30% of all triple-negative breast cancer cases—a combination of Trodelvy and Merck's Keytruda reduced the risk of tumor progression or death by 35%.

“For more than twenty years, patients with mTNBC have had limited choices in first-line treatment. Building on its impact in second-line mTNBC, Trodelvy now offers patients a powerful new backbone therapy option in the first-line setting,” said Dietmar Berger, Chief Medical Officer, Gilead Sciences, in a statement.

Read More: Ozempic-Like Weight-Loss Drugs May Cut Breast Cancer Risk By A Third, Finds Research

In a separate clinical trial, AstraZeneca's Datroway reduced the risk of tumor progression or death by 43% compared with chemotherapy. The drug also extended median progression-free survival by five months.

“Datopotamab deruxtecan (brand name Datroway) is the first and only medicine to significantly prolong overall survival in the 1st-line setting compared to chemotherapy in patients with metastatic triple-negative breast cancer who are not candidates for immunotherapy. This approval will bring a much-needed treatment option for these patients,” said Tiffany A. Traina, Triple-Negative Breast Cancer Clinical Research Program, Memorial Sloan Kettering Cancer Centre, part of the study.

Burden Of Triple-negative Breast Cancer

Read To Know: More Indian Women Turning To Egg Freezing For Future Family Planning: Know The Risks And Benefits

Triple-negative breast cancer (TNBC) represents about 10–15% of global breast cancer cases but accounts for a disproportionately high share of mortality. In 2025, more than 48,000 Americans were diagnosed with triple-negative breast cancer.

The disease is known for its aggressive nature. On average, triple-negative breast cancer recurs or spreads within about 2½ years, compared with around five years for other forms of breast cancer. Additionally, nearly half of patients never receive a second line of treatment.

Both AstraZeneca and Gilead are now investigating their therapies in earlier stages of breast cancer.